Search for "influenza"

Filter search results

  • Infectious Disease (119)
  • Clinical Trials (86)
  • Covid-19 (61)
  • The next chapter of clinical trial services (31)
  • Suvoda WP (29)
  • Therapy Area (29)
  • COVID Cross-sector Impact Brief (22)
  • Drug Development (20)
  • Country Risk Report Q4 2021 - Professional Services (19)
  • Approvals (9)
  • Technology (9)
  • API Manufacturers (7)
  • Genomics (7)
  • Cytiva-Cell & Gene Therapy WP 2 (5)
  • Respiratory (5)
  • Agilent WP (4)
  • Global Healthcare and Pharma Market Outlook (4)
  • Business & Regulation (3)
  • Immunology (3)
  • Regulation (3)
  • News Analysis and Comments (161)

    No Filter Selected

  • Clinical Trials (2)

    No Filter Selected

  • United States (57)
  • Australia (8)
  • United Kingdom (7)
  • India (6)
  • Japan (6)
  • Europe (5)
  • Global (4)
  • North America (4)
  • China (3)
  • Brazil (2)
  • Germany (2)
  • Middle East & Africa (2)
  • Argentina (1)
  • Asia-Pacific (1)
  • Canada (1)
  • Mexico (1)
  • Panama (1)
  • Poland (1)
  • Slovakia (1)
  • South Africa (1)

    No Filter Selected

  • Other Innovation Areas (1)
Showing 20 results out of 161

Snapshot H1N1 (swine influenza) – the post-pandemic pipeline

Few modern pandemics created as much global furore as the H1N1 swine flu outbreak which struck in 2008. The scale and spread of the outbreak created a very real sense of fear about mutating virus strains and created a boom for a new pipeline of vaccines and antivirals. Using detailed market data, we find out what the future holds for the industry in this post-pandemic period.